ReviewCardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review
Section snippets
Literature search
A systematic literature search was performed using databases of Medline, Embase and Cochrane Library. The keywords used for the Medline search were: (“Arthritis, Rheumatoid/epidemiology”[Mesh:NoExp] or “Arthritis, Rheumatoid/ultrasonography” [Mesh:NoExp] or “Arthritis, Rheumatoid/complications” [Mesh:NoExp] or “Arthritis, Rheumatoid/drug therapy”[Mesh:NoExp] or “Arthritis, Rheumatoid/mortality”[Mesh:NoExp]) and (“Cardiovascular Diseases”[Mesh:NoExp] or “Heart Diseases”[Mesh:NoExp] or
Results
The literature search on electronic databases identified 1138 titles (Fig. 1) and 277 articles were selected after reviewing the titles and abstracts. Finally, 34 studies were included in the analysis and three abstracts from international congresses were added.
Discussion
This systematic literature review showed a poor association between LD-CT and CV risk factors and identified a trend of increasing major CV events. LDC exposure might have a beneficial effect on lipid profile, no effect on blood pressure and an increase in insulin resistance. The analysis of surrogate markers revealed no risk of atherosclerosis with LD-CT and no effect on cardiac function. The effect of LD-CT on arterial stiffness is not clear since two studies did not find any change [39], [40]
Conflict of interest statement
The authors received a grant support from Abbott.
Acknowledgments
The authors thank Abbott for an institutional support for this study, Philippe Gaudin, Daniel Wendling, Alain Cantagrel, Pascal Claudepierre, Jean-Francis Maillefert, Thierry Schaeverbeke and Jacques Tebib for their help in elaborating the study and interpretation of the data.
References (50)
- et al.
Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
Joint Bone Spine
(2006) Is atherosclerosis a complication of long-term corticosteroid treatment?
Am J Med
(1986)- et al.
Coronary aneurysms after stent placement: a suggestion of altered vessel wall healing in the presence of anti-inflammatory agents
J Am Coll Cardiol
(1991) - et al.
Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study)
J Am Coll Cardiol
(2002) - et al.
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis
Atherosclerosis
(2008) - et al.
Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease
Semin Arthritis Rheum
(2004) - et al.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors
Arthritis Rheum
(2001) - et al.
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis
Circulation
(2003) - et al.
Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis
J Rheumatol
(2003) - et al.
Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis
Circulation
(2003)
Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?
Arthritis Rheum
Glucocorticoids and insulin resistance: old hormones, new targets
Clin Sci (Lond)
Cushing, cortisol, and cardiovascular disease
Hypertension
Does altered glucocorticoid homeostasis increase cardiovascular risk?
Cardiovasc Res
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease
Ann Intern Med
Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study
J Rheumatol
Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis
Arthritis Rheum
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy
Scand J Rheumatol
Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis
Clin Rheumatol
High HDL cholesterol in women with rhematoid arthritis on low-dose glucocorticoid therapy
Eur J Clin Invest
Body composition in rheumatoid arthritis
Br J Rheumatol
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis
Arthritis Rheum
Incidence of adverse effects during long-term, low-dose glucocorticoid treatment of rheumatoid arthritis
Arthritis Rheum
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial
Ann Intern Med
Glucocorticoids and insulin sensitivity in rheumatoid arthritis
J Rheumatol
Cited by (89)
Use of Glucocorticoids in Patients With Cancer: Potential Benefits, Harms, and Practical Considerations for Clinical Practice
2023, Practical Radiation OncologyManagement and long-term outcomes of patients with chronic inflammatory diseases experiencing ST-segment elevation myocardial infarction: The SCALIM registry
2022, Archives of Cardiovascular DiseasesCitation Excerpt :Nonetheless, their prescription could induce or worsen many cardiovascular risk factors such as hypertension, dyslipidaemia and diabetes [36]. Furthermore, long-term corticosteroid therapy promotes atherosclerosis progression and increases cardiovascular mortality and myocardial infarction [37]. Pujadas-Rodriguez et al. observed an increased risk of cardiovascular disease associated with glucocorticoid dose intake, even at lower doses (< 5 mg), in six immune-mediated diseases (giant cell arteritis, polymyalgia rheumatica, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and vasculitis) [38].
Animal models to study pathogenesis and treatments of cardiac disorders in rheumatoid arthritis: Advances and challenges for clinical translation
2021, Pharmacological ResearchCitation Excerpt :Finally, although still a matter of debate, anti-TNFα are suspected to promote heart failure in RA patients [39]. Exploring cardiac features in cohorts of RA patients is challenging because of heterogeneity in disease severity and duration in RA cohorts, heterogeneity in current therapies including conventional, biologic, targeted DMARDs and a high level of polymedication including CV drugs or anti-inflammatory drugs such as corticoids which can impact upon cardiac function [40]. In this context, preclinical studies using animal models of arthritis may help the discovery of pathophysiological mechanisms and/or new drugs or therapeutic approaches.
Risk factors for hypertension in rheumatoid arthritis patients–A systematic review
2021, Autoimmunity ReviewsCitation Excerpt :Studies indicate that the CV risk associated with corticosteroids may depend on dose, inconsistent with the findings of Wolfe et al. For example, a systematic review found that low doses of corticosteroids were not associated with major CV events in RA patients [53]. In a large study of approximately 72, 000 patients with chronic inflammatory diseases, incident HTN rates increased with increasing prednisone dose [54].
Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?
2019, Autoimmunity ReviewsCitation Excerpt :One meta-analysis of nine randomized controlled trials (RCTs) involving patients with osteoarthritis (OA) and RA has found that, in comparison with placebo, the use of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) has no significant effect on CVD events [16], but no RCT has directly investigated whether any anti-inflammatory agent can reduce the rate of such events in RA patients or the general population, and the published data are conflicting. For example, a systematic literature review assessing CVD risk in RA patients receiving low corticosteroid doses (defined as <10 mg/day of prednisone) found that they had a protective effect on serum lipid profiles, increased insulin resistance or glycemia, probably had no effect on blood pressure, had no effect on atherosclerosis, ventricular function or heart rate variability, had discordant effects on arterial stiffness, and were associated with major CV events such as myocardial infarction (MI) (hazard ratio [HR]1.7 [1.2–o2.3]), stroke (odds ratio [OR] 4.36 [1.60–11.90]), mortality (HR 2.03 [1.25–3.32]) and, in patients with rheumatoid factor-positive RA, a composite index of CV events (HR 2.21 [1.22–4.00]) [17]. In brief, there was weak association with cardiovascular risk, but a trend toward an increase in major CV events [17,18].